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Abstract
Over 1000 disease-causing missensemutations have been found in humanβ-cardiac,α-cardiac, embryonic and adult fast myosin
2a myosin heavy chains. Most of these are found in human β-cardiac myosin heavy chain. Mutations in β-cardiac myosin cause
hypertrophic cardiomyopathy predominantly, whereas those in α-cardiac are associated with many types of heart disease, of
which the most common is dilated cardiomyopathy. Mutations in embryonic and fast myosin 2a affect skeletal muscle function.
This review provides a short overview of the mutations in the different myosin isoforms and their disease-causing effects.
Keywords β-Cardiac myosin . α-Cardiac myosin . Embryonic myosin . Cardiac disease . Skeletal muscle disease . Missense
mutation
Abbreviations
FHC Familial hypertrophic cardiomyopathy
HCM Hypertrophic cardiomyopathy
DCM Dilated cardiomyopathy
LDM Laing distal myopathy
MSM Myosin storage myopathy
S1 Subfragment-1 (myosin motor domain)
S2 Subfragment-2
LMM Light meromyosin (myosin tail)
RLC Regulatory light chain
ELC Essential light chain
Introduction
Myosins are molecular motors, which bind actin and nucleo-
tide, and use the chemical energy from ATP hydrolysis to
drive movement. The human genome encodes 38 myosin
genes, organised into 12 classes. The largest class of myosin
is class 2 (Peckham 2016).Myosins in this class are comprised
of two heavy chains, and four light chains, of which two are
essential, and two are regulatory. The two heavy chains
dimerise to form a long coiled-coil tail, which enables these
proteins to assemble into filaments.
Striated muscle myosin isoforms are all class 2 myosins.
One or more disease mutations have been described for these
isoforms, with missense mutations most common. Four iso-
forms (β-cardiac, α-cardiac, embryonic and adult fast myosin
2a) are most commonly mutated. The most commonly mutat-
ed of these is β-cardiac myosin heavy chain (MYH7:
Uniprot), which is expressed in both cardiac and in slow skel-
etal muscle and in developing muscle fibres (Schiaffino and
Reggiani 2011). Over 1000 mutations have been reported, of
which the majority (92%) are missense. In the adult heart, it is
mainly found in the ventricles and mutations in the gene
encoding this protein mainly cause hypertrophic cardiomyop-
athy (HCM) (Supplemental Table 1, Fig. 1). α-Cardiac myo-
sin heavy chain (MYH6: uniprot) is the next most commonly
mutated. It is almost exclusively expressed in the heart, where
it is mainly found in the atria (Bouvagnet et al. 1989). Out of a
total of 145 mutations, 128 are missense. These mutations are
associated with HCM and dilated cardiomyopathy (DCM)
and at least 6 other disease phenotypes in the heart
(Supplementary Table 2, Fig. 1).
Two skeletal myosin heavy chains have also been reported
to have more than 10 mutations. Embryonic myosin heavy
chain (MYH3: Uniprot) is the first myosin isoform to be
expressed in developing muscle fibres, is re-expressed in the
early stages of muscle regeneration in adults and is expressed
in some specialised adult muscles (Schiaffino et al. 2015).
Twenty-six missense mutations in this gene have been
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reported, of which most are associated with distal
arthrogryposis (Supplementary Table 3). Twenty-six mis-
sense mutations have been reported for myosin heavy chain
2A (MyHC2a: MYH2: Uniprot), which is found in fast skel-
etal muscle fibres (Type 2A) (Schiaffino et al. 2015).
Mutations in its gene are associated with myopathies
(Supplementary Table 4).
In this review, we have revisited our previous analysis of
the positions of the known disease-causing mutations in theβ-
cardiac myosin heavy chain sequence (Colegrave and
Peckham 2014) and extended it to α-cardiac, embryonic and
adult fast myosin 2a. The clustering of the disease mutations
into important functional regions in β-cardiac myosin heavy
chain is similar to that of our earlier study. Mutations in α-
cardiac, embryonic and adult fast myosin 2a, although much
smaller in number, are also largely distributed throughout the
sequence, and found in key functional regions.
Myosin structure—a brief overview
The structure of myosin motor domains has been solved many
times (e.g. see Houdusse and Sweeney (2016)) and is only
reviewed briefly here. The motor and light chain–binding do-
mains make up subfragment-1 (S1) of myosin (comprised of
25K, 50K and 20K subdomains (Rayment et al. 1993)). The
N-terminal 25K domain comprises the N-terminal ‘SH3’ like
fold, 6 of the 7 strands in the 7-stranded β-sheet core, and the
‘GESGAGKT’ motif for the well-conserved phosphate-bind-
ing loop at the base of the nucleotide-binding pocket. The
junction between the 25K and central 50K domain lies within
loop 1, just after the phosphate-binding loop. This domain is
separated into two functional domains known as the upper and
lower 50K domains. Two motifs, switch 1 and switch 2
(Geeves and Holmes 1999), respond to the binding of ATP
in the nucleotide pocket by moving close together when ATP
is bound, and further apart after phosphate is released, con-
veying information about the occupancy of the nucleotide
pocket to the rest of the molecule.
On phosphate release, the cleft between the upper and low-
er 50K domains closes, the converter and light chain–binding
domain undergo a large transition, such that the lever (mostly
comprised of the LCD) swings by a large angle (Geeves and
Holmes 1999). When bound to actin, it is this movement of
the lever that drives movement of the actin filaments, and
hence contraction. Loop 1, which lies above the nucleotide-
binding pocket, may modulate the ATPase kinetics of the
motor, and in particular the rate of ADP release (Uyeda
et al. 1994). The actin-binding regions within myosin are
mainly comprised of loops 2, 3 and 4, the HCM loop, the
activation loop and the helix-loop-helix (von der Ecken et al.
2016).
The motor domain and lever are followed by an α-helical
region that homodimerises to form a coiled coil, beginning at
the invariant proline (residue 838, Fig. 1). The coiled coil has a
characteristic 7 heptad amino acid residue repeat (abcdefg) in
which the ‘a’ and ‘d’ residues tend to be buried in the hydro-
phobic seam. The first part of the coiled coil forms a region
known as subfragment-2 (S2, here defined as residues 838-
1217). The remainder of the coiled coil is known as light
meromyosin (LMM) and is the filament forming region of
the myosin heavy chain. Twenty-eight residue repeats of al-
ternating charge enable the LMM to pack together into fila-
ments with a defined stagger between each molecule
(McLachlan and Karn 1982). Four ‘skip’ residues (Offer
1990) interrupt this regular repeat within the coiled coil and
the structures of the coiled coil in these 4 regions were recently
solved (Taylor et al. 2015).
It has recently become clear that myosin heads interact
with each other to form the ‘interacting heads motif’
(IHM) in striated muscle isoforms, similar to that origi-
nally described to non-muscle and smooth muscle myosin
(Wendt et al. 2001). In the IHM, in the filament, the two
myosin heads are thought to interact with S2 (Alamo et al.
2017; Woodhead and Craig 2020), as well as with
myosin-binding protein C (MyBPC (Spudich 2015). The
formation of IHM is correlated with a low ATPase activ-
ity (McNamara et al. 2015), thus helping to conserve ATP
usage by muscles when not in use. Activation of the mus-
cle not only involves the canonical movement of tropo-
myosin on the thin filament to expose binding sites for
myosin heads but also additionally requires myosin heads
to be released from their shutdown state (Irving 2017). It
is likely that phosphorylation of the regulatory light
chains (RLCs) plays a role in this in both cardiac and
skeletal muscles (Yu et al. 2016), through affecting the
stability of the shutdown state.
Fig. 1 Analysis of myosin mutations in myosin heavy chains. a Graph
showing the pattern of missense mutations that occur along the length of
the β-cardiac myosin heavy chain amino acid sequence. Data shown
includes mutations in this and an earlier study in 2014 with fewer muta-
tions (Colegrave and Peckham 2014). The total numbers of mutations for
each stretch of 50 amino acids (for subfragment-2 (S1) and subfragment-2
(S2)) and for 100 amino acid stretches (for light meromyosin (LMM)) are
shown. Key functional regions of the motor are identified. LCD, light
chain–binding domain. b Chart to indicate the main diseases resulting
from mutations in β-cardiac myosin heavy chain (see also
Supplementary Table 1). HCM, hypertrophic cardiomyopathy; DCM,
dilated cardiomyopathy; CM, cardiomyopathy; SCD, sudden cardiac
death; LVNC, left ventricular non-compaction. c Graph showing the pat-
tern of missense mutations that occur along the length of the α-cardiac
myosin heavy chain amino acid sequence, as in a. d Chart to indicate the
main diseases resulting from mutations in α-cardiac myosin heavy chain
(see also Supplementary Table 2). Abbreviations as in b. Additional
abbreviations: SUD, sudden unexplained death; LVO, left ventricular
obstruction. e Percentage of mutations in the three main regions of myo-
sin, S1 (motor and lever), S2 and LMM for the 4 different myosin heavy
chains
R
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Mutations in β-cardiac myosin heavy chain
and disease
Almost 1000 mutations in the gene that encodes β-cardiac
myos in heavy cha in have now been desc r ibed
(Supplementary Table 1). These mutations were retrieved
from the professional version of the Human Gene Mutation
Database (HGMD: (Stenson et al. 2017), an up-to-date ver-
sion of the HGMD run by the Institute of Medical Genetics in
Cardiff. Each mutation described in this database is curated
from peer-reviewed publications, and classified as disease
causing, or probable/possible disease causing based on this
published evidence (see associated references in
Supplementary Table 1). Other mutation databases are also
available and are useful, such as ClinVar (Landrum et al.
2016) and the Leiden open variation database (LOVD:
http://www.lovd.nl (Harrison et al. 2016). However, a signif-
icant number of mutations (~ 40%) in these databases are
directly submitted and lack supporting evidence from a peer-
reviewed publication, and should be viewed with more
caution.
Although the number of mutations in the HGMD database
has almost doubled compared with that reported 5 years ago
(Colegrave and Peckham 2014), the pattern of mutations is
similar (Fig. 1a). The majority (~ 58%) of the HCMmutations
in β-cardiac myosin are found in the motor domain and lever
(S1). Approximately 15% of mutations are found in S2 and
the remaining mutations (27%) are found in LMM.
The majority (73%) of the missense mutations in β-cardiac
myosin heavy chain cause HCM (Fig. 1b), and these muta-
tions are found throughout the sequence (Fig. 1a). The first
mutation to be linked to this disease was the R403Q mutation,
which lies within a loop known as the HCM loop in the motor
domain (Geisterfer-Lowrance et al. 1990). With so many mu-
tations reported, there is little experimental work on most of
them, and mutations identified may, in some cases, correlate
with disease rather than being causal. HCMmay affect up to 1
in 200 of the population (Semsarian et al. 2015), is the most
common cause of sudden death in the under 30 age group, and
mutations inβ-cardiac myosin heavy chain are responsible for
~ 40% of cases of HCM (Maron 2002).
The second most common disease arising from mutations
in the MYH7 gene is dilated cardiomyopathy (DCM).
Mutations in MYH7 account for about 4% of all DCM, and
the analysis here shows that 14% of all the mutations in
MYH7 cause dilated cardiomyopathy. However, in a few res-
idues, a missense mutation has been associated with either
HCM or DCM (Supplementary Table 1, Fig. 2). DCM is
caused by as many as 32 different genes, and while DCM
was thought to be less common than HCM, it has recently
been estimated to affect as many as 1 in 250 individuals
(Hershberger et al. 2013).
About 5% of mutations are associated with left ventricular
non-compaction (LVNC) (Fig. 1b, Supplementary Table 1).
Reports of this disease are becoming more common (Towbin
et al. 2015). In the embryonic heart, the myocytes are relative-
ly loosely arranged into a spongy myocardium. During devel-
opment, these cells become more organised and compacted.
However, in LVNC, this compaction is incomplete, and the
myocardium tends to contain multiple trabeculae as a result,
affecting blood flow through the left ventricular chamber of
the heart. LVNC can be associated with Ebstein’s anomaly
(Attenhofer Jost et al. 2007), which involves a malformation
of the tricuspid valve and an altered right ventricle, as well as
defects in the septum, separating the left and right ventricle.
About 4% of mutations apparently have little effect on the
heart, but mainly cause skeletal muscle myopathies such as
Laing distal myopathy (LDM), myosin storage myopathy
(MSM), hyaline body myopathy and multi-minicore disease,
collectively known as myosinopathies (Tajsharghi and
Oldfors 2013). Most of these mutations are found in a specific
region of the coiled-coil tail (Colegrave and Peckham 2014),
Supplementary Table 1), and commonly involve a mutation to
a proline residue, or a deletion of a single amino acid, which
likely disrupts the coiled coil (Parker et al. 2018). The intrigu-
ing question still remains as to why these mutations are not
always associated with a cardiac phenotype.
An analysis of the positions of these mutations against their
amino acid location shows that the ‘hot spots’ or peaks where
mutations are more common are similar to those found in
earlier studies with fewer mutations (Buvoli et al. 2008;
Colegrave and Peckham 2014). These hot spots tend to be in
key functional areas (Figs. 1a and 2, Supplemental Table 1).
For example, 14 missense mutations are found in loop 1, and
thus expected to affect the ATPase cycle. Mutations in loops
3, 4 and 2, the activation loop, the HCM loop and the helix-
loop-helix motif, all proposed to enable the interaction of my-
osin with actin, account for 5% of all the mutations
(Supplementary Table 1). There are 21 mutations in the relay
helix, and 56 in the converter accounting for 8% of the total
number of mutations. The pliant region, which is just 6
Fig. 2 Positions of mutations each of the four myosin heavy chains.
MYH7—β-cardiac myosin heavy chain, MYH6—α-cardiac myosin
heavy chain, MYH3—embryonic myosin heavy chain and MYH2—
MyHC2A. (See Supplemental Tables 1-4 for a list of the mutations and
associated references). In subfragment-1 (S1), functional regions of the
motor and lever are indicated. In subfragment-2 (S2), the three ‘rings’ of
acidic residues are indicated. The 4 skip residues in LMMare highlighted.
The heptad repeat of the coiled-coil sequence is indicated below the
amino acid residues. Diseases caused by mutations in specific residues
are shown in coloured font, as indicated by the legend. One to 2 mutations
in the same residue are indicated by a box around the residue. Boxes are
coloured differently to the residue if a second mutation causes a different
disease. Residues in which there are more than 3 mutations are indicated
by the number above the residue. Downward arrows indicate residues in
which there is a mutation in 3 out of the 4 sequences
R
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residues long, is highly mutated, with 13 mutations reported
for this region. This sequence immediately follows the con-
verter domain, providing an important connection between it
and the light chain–binding domain (LCD), which forms the
majority of the lever, and itself has over 30 mutations. The
majority of the missense mutations in the myosin head are
thus likely to affect force output by altering the ATPase cycle,
the ability of myosin to interact with actin, or by transmission
of force or movement by the lever.
Fifteen percent of the missense mutations in β-cardiac my-
osin heavy chain are found in subfragment-2 (S2)
(Supplementary Table 1). Of the 191 mutations in S2, almost
60% are found in the first 120 residues, which contains three
‘rings’ of acidic residues (Fig. 2), interspersed by regions of
basic residues. The myosin head has been shown to interact
with the first ring of charge in its shutdown state, and muta-
tions in the first charged ring may destabilise the formation of
the IHM (Alamo et al. 2017). This interaction has been sug-
gested to be mediated by loop 2 and the HCM loop, and thus,
mutations in these loops may also affect the ability of myosin
to form the shutdown state. Mutations in the second charged
ring are likely to affect the ability of cMyBPC (cardiac
myosin-binding protein C) to bind to myosin as discussed
earlier (Colegrave and Peckham 2014), which would be ex-
pected to affect the ability of cMyBPC to modulate the con-
tractile output of the heart.
The remaining 26% of mutations are found in LMM (Fig.
1a, Supplementary Table 1). Fifty-six percent cause HCM,
21% DCM, 14% cause skeletal muscle myopathy and 7%
cause LVNC. Interestingly, while only 20% of the myosin
mutations that cause HCM are found in LMM, this rises to
27% for LVNC, 38% for DCM and 90% for myopathy. The
myopathy causing mutations are mostly found towards the
distal end of LMM from residues 1430 onwards. Overall,
the pattern of mutations in this region is again similar to that
described earlier (Colegrave and Peckham 2014).
Mutations in α-cardiac, embryonic
and MyHC2Amyosin heavy chain and disease
Mutations inα-cardiac myosin heavy chain are almost 10-fold
less common than those in β-cardiac myosin heavy chain
(Fig. 1c, Supplementary Table 2), with only 128 missense
mutations described in HGMD. These mutations result in a
wide range of cardiac diseases (Fig. 1d), of which DCM is the
most common outcome (24%). The mutations occur through-
out the sequence, with 45% occurring in the myosin head
(S1), 19% in S2 and 35% in LMM. Thus, mutations in
LMM are relatively more common in α-cardiac than in β-
cardiac myosin heavy chain. With a lower number of muta-
tions, a pattern is harder to spot, but mutations are relatively
common in loop 1 and in the region of (but not in) the HCM
loop. Interestingly, more mutations seem to occur in the distal
region of S2 compared with the proximal region, in contrast to
mutations in S2 in β-cardiac myosin heavy chain.
Mutations in the two skeletal myosin specific isoforms are
still relatively uncommon, with 26 in MyHC2a and 34 in
embryonic myosin heavy chain (Supplementary Tables 3 &
4, sourced from HGMD). Most of the mutations in embryonic
myosin heavy chain (76%) are found in the S1, and interest-
ingly, very few are found in S2 (Fig. 1e). Mutations in this
myosin heavy chain cause Freeman-Sheldon (FSS) and
Sheldon-Hall syndromes (Toydemir et al. 2006), both forms
of arthrogryposis (severe multiple congenital contractures).
These two syndromes are two of 10 different types of
arthrogryposes and both strongly affect orofacial muscles.
Three FSS mutations found in the motor domain resulted in
a decreased rate of ATP hydrolysis, and of binding of ATP to
myosin. This would be expected to reduce the rate at which
the myosin head can detach from actin, and then increase the
time in which the myosin remains detached from actin
(Walklate et al. 2016). Embryonic myosin plays a key role
in early muscle development, and its ablation in mice results
Fig. 3 Cris dos Remedios and
colleagues at a Gordon
Conference
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in scoliosis (Agarwal et al. 2020), a phenotype also shown by
Freeman-Sheldon syndrome patients, as well as numerous
other defects.
Mutations in MyHC2A have only been relatively recently
reported, with the first mutation described in 2000
(Martinsson et al. 2000). These mutations typically cause a
variety of myopathies (Supplementary Table 4, sourced from
HGMD), often associated with external ophthalmoplegia
(weakness of the eye muscles), and type 2A muscle fibres
are small or lacking. The distribution of missense mutations
in MyHC2A is similar to that of the other myosins, with 58%
in S1, 20% in S2 and 23% in LMM (Fig. 1e). To date, very
little is known about the effects of these mutations on
function.
Discussion
The aim of this review was to briefly update our earlier anal-
ysis of mutations inβ-cardiac myosin heavy chain (Colegrave
and Peckham 2014) and extend it to three further myosin
heavy chains in which mutations have begun to be reported.
Despite the doubling in numbers of mutations described forβ-
cardiac myosin heavy chain in just 6 years, the overall pattern
of mutations is somewhat similar to that described earlier. A
similar pattern seems to be emerging for α-cardiac myosin
heavy chain, with perhaps a slightly higher frequency of mu-
tations in the filament forming region of this myosin. We still
have much to learn about how these mutations exert their
effects and how the expression of other myosin isoforms
might change and compensate for or contribute to the overall
phenotype of these disease mutations.
Reflection on my interactions with Cris dos
Remedios
I could not write this brief review without thinking back on
my interactions with Cris over my career. I first remember
meeting Cris when I was a PhD student, working with
Roger Woledge in the Department of Physiology at
University College London on muscle energetics. Roger was
due to go to the International Union of Physiological Sciences
meeting in Sydney, Australia, in 1983. Unfortunately, he was
unable to go and sent me instead! It was the first time I had
ever flown, and it was a harsh introduction to the effects of jet-
lag. I proudly presented my poster, and in an oral discussion
session, Cris (who was chairing) asked me to briefly discuss
my findings with the audience. He then very kindly invited me
back to his house for a party he was holding for the muscle
research community.
I have since met up with Cris on multiple occasions, and
most recently we ran a session together in Edinburgh at the
Joint 19th International Union of Pure and Applied
Biophysics (IUPAB) and 11th European Biophysical
Societies’ Association (EBSA) Congress in Edinburgh,
Scotland, in July 2017. Cris was as enthusiastic as when I first
met him all those years ago. He has been a major contributor
to the field of muscle research (Fig. 3), and his contribution
towards setting up the Sydney Heart Bank was a major
achievement towards understanding cardiac disease.
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